Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Limited has issued 1,273,363 fully paid ordinary shares following the exercise of various unlisted options. This issuance was conducted without disclosure to investors under the relevant sections of the Corporations Act, and the company has confirmed compliance with necessary legal provisions. The announcement reflects Orthocell’s strategic moves to strengthen its financial position, potentially impacting its capability to advance its product development and market reach.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their product portfolio includes the CelGro™ platform of collagen medical devices, Striate+™ for dental applications, Remplir™ for peripheral nerve reconstruction, and SmrtGraft™ for tendon repair. The company is working on accelerating the development of its tendon cell therapy in the US.
YTD Price Performance: 15.87%
Average Trading Volume: 1,716,032
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$376.7M
See more data about OCC stock on TipRanks’ Stock Analysis page.
